Neurodevelopmental delay in children exposed to maternal SARS-CoV-2 in-utero

• Verfasst von: Fajardo-Martinez, Viviana [VerfasserIn]
• Verfasst von: Ferreira, Fatima [VerfasserIn]
• Verfasst von: Fuller, Trevon [VerfasserIn]
• Verfasst von: Cambou, Mary Catherine [VerfasserIn]
• Verfasst von: Kerin, Tara [VerfasserIn]
• Verfasst von: Paiola, Sophia [VerfasserIn]
• Verfasst von: Mok, Thalia [VerfasserIn]
• Verfasst von: Rao, Rashmi [VerfasserIn]
• Verfasst von: Mohole, Jyodi [VerfasserIn]
• Verfasst von: Paravastu, Ramya [VerfasserIn]
• Verfasst von: Marschik, Dajie [VerfasserIn]
• Verfasst von: Marschik, Peter B. [VerfasserIn]
• Verfasst von: Iyer, Sai [VerfasserIn]
• Verfasst von: Kesavan, Kalpashri [VerfasserIn]
• Verfasst von: Borges Lopes, Maria da Conceição [VerfasserIn]
• Verfasst von: Britto, José Augusto A. [VerfasserIn]
• Verfasst von: Moreira, Maria Elisabeth [VerfasserIn]
• Verfasst von: Brasil, Patricia [VerfasserIn]
• Verfasst von: Nielsen-Saines, Karin [VerfasserIn]
• Titel: Neurodevelopmental delay in children exposed to maternal SARS-CoV-2 in-utero
• Verf.angabe: Viviana Fajardo-Martinez, Fatima Ferreira, Trevon Fuller, Mary Catherine Cambou, Tara Kerin, Sophia Paiola, Thalia Mok, Rashmi Rao, Jyodi Mohole, Ramya Paravastu, Dajie Zhang, Peter Marschik, Sai Iyer, Kalpashri Kesavan, Maria da Conceição Borges Lopes, José Augusto A. Britto, Maria Elisabeth Moreira, Patricia Brasil & Karin Nielsen-Saines
• Jahr: 2024
• Umfang: 11 S.
• Illustrationen: Illustrationen
• Fussnoten: Online veröffentlicht: 24. Mai 2024 ; Gesehen am 30.01.2025
• Titel Quelle: Enthalten in: Scientific reports
• Ort Quelle: [London] : Springer Nature, 2011
• Jahr Quelle: 2024
• Band/Heft Quelle: 14(2024), Artikel-ID 11851, Seite 1-11
• ISSN Quelle: 2045-2322
• DOI: doi:10.1038/s41598-024-61918-2
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Paediatric research
• Sach-SW: Viral infection
• K10plus-PPN: 1916036090

Abstract

It is unclear if SARS CoV-2 infection during pregnancy is associated with adverse neurodevelopmental repercussions to infants. We assessed pediatric neurodevelopmental outcomes in children born to mothers with laboratory-confirmed SARS CoV-2 infection during pregnancy. Neurodevelopmental outcomes of in-utero exposed children were compared to that of pre-pandemic control children in Los Angeles (LA), CA, USA and Rio de Janeiro, Brazil. Bayley Scales of Infant and Toddler Development, 3rd edition (Bayley-III), the gold standard tool for evaluating neurodevelopment until 36 months of age and Ages and Stages Questionnaires (ASQ-3), a frequently used screening instrument for evaluating neurodevelopment in this same age group were the assessment tools used. Developmental delay (DD) was defined as having a score < − 2 SD below the norm (< 70) in at least one of three Bayley-III domains, (cognitive, motor or language) or a score below the cut-off (dark zone) in at least one of five ASQ-3 domains (communication, gross motor, fine motor, problem solving, personal-social). Exposed children were born between April 2020 and December 2022 while control children were born between January 2016 to December 2019. Neurodevelopmental testing was performed in 300 children total: 172 COVID-19 exposed children between 5-30 months of age and 128 control children between 6-38 months of age. Bayley-III results demonstrated that 12 of 128 exposed children (9.4%) had DD versus 2 of 128 controls (1.6%), p = 0.0007. Eight of 44 additional exposed children had DD on ASQ-3 testing. Fully, 20 of 172 exposed children (11.6%) and 2 of 128 control children (1.6%), p = 0.0006 had DD. In Rio, 12% of exposed children versus 2.6% of controls, p = 0.02 had DD. In LA, 5.7% of exposed children versus 0 controls, p = 0.12 had DD. Severe/critical maternal COVID-19 predicted below average neurodevelopment in the exposed cohort (OR 2.6, 95% CI 1.1-6.4). Children exposed to antenatal COVID-19 have a tenfold higher frequency of DD as compared to controls and should be offered neurodevelopmental follow-up.